Sign In
14 Nov 2016 07:00
Ā
14 November 2016 | AIM: RENE |
Ā
ReNeuron Group plc
("ReNeuron" or "the Company")
Ā
Notification of Interim Results
Ā
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, intends to announce its interim results for the six months ended 30 September 2016 on Monday 5 December 2016.
Ā
The Company also expects to announce initial three month follow-up data from the PISCES II clinical trial of its CTX cell therapy candidate for stroke disability on the same day.
Ā
A meeting for analysts will be held at 9.00am on the morning of 5 December 2016 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
Ā
For a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 9.00am on the day of the results:
Ā
http://vm.buchanan.uk.com/2016/reneuron051216/registration.htm
Ā
A recording of the presentation will be made available on ReNeuron's and Buchanan's websites, www.reneuron.com and www.buchanan.uk.com
Ā
Ā
Enquiries:
Ā
ReNeuron | +44 (0)20 3819 8400 |
Olav HellebĆø , Chief Executive Officer | Ā |
Michael Hunt, Chief Financial Officer | Ā |
Buchanan | +44 (0) 20 7466 5000 |
Mark Court, Sophie Cowles, Stephanie Watson | Ā |
Stifel Nicolaus Europe Limited | +44 (0) 20 7710 7600 |
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) | Ā |
Ā
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
Ā
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.
Ā
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.
Ā
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
Ā
Ā
Follow the stocks
